GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
22.40
-0.20 (-0.87%)
At close: 3:17PM EST
Stock chart is not supported by your current browser
Previous close22.60
Open22.40
Bid0.00 x 0
Ask0.00 x 0
Day's range22.39 - 22.97
52-week range18.14 - 23.12
Volume6,518
Avg. volume4,344
Market cap112.547B
Beta (3Y monthly)0.37
PE ratio (TTM)45.16
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.18 (5.28%)
Ex-dividend date2020-02-20
1y target estN/A
  • Forget a cash ISA! I’d invest in these 3 FTSE 100 shares to double my State Pension
    Fool.co.uk

    Forget a cash ISA! I’d invest in these 3 FTSE 100 shares to double my State Pension

    Why I’d aim to compound my money with these 3 great stocks.

  • The GlaxoSmithKline (LON:GSK) Share Price Is Up 27% And Shareholders Are Holding On
    Simply Wall St.

    The GlaxoSmithKline (LON:GSK) Share Price Is Up 27% And Shareholders Are Holding On

    Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking...

  • Reuters - UK Focus

    UPDATE 4-UK bribery investigation adds to Glencore's legal headaches

    The UK's Serious Fraud Office (SFO) has launched a bribery investigation into Glencore , adding to legal troubles that have hit the shares of one of the world's biggest miners and commodity traders. The SFO said on Thursday it had opened an investigaton into suspicions of bribery in the conduct of business by the Glencore group of companies, its officials, employees, agents and associated persons in June.

  • Top shares for December 2019
    Fool.co.uk

    Top shares for December 2019

    We asked our freelance writers to share their top stock picks for the month.

  • Measuring the quality of GlaxoSmithKline (LON:GSK) as an investment
    Stockopedia

    Measuring the quality of GlaxoSmithKline (LON:GSK) as an investment

    A company with a high Quality Rank has strong cash-generation, consistent profits, high rates of return on investment, high margins and robust financial health8230;

  • Reuters - UK Focus

    Sanofi weighing options for consumer healthcare unit-sources

    FRANKFURT/PARIS, Nov 21 (Reuters) - Sanofi is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month. An initial public offering (IPO) of the unit, which could be worth around $30 billion according to two sources familiar with the matter, is also on the cards. Sources cautioned that no final decision had been made.

  • India Plans Incentives to Bring In Foreign Manufacturers From Tesla to Glaxo
    Bloomberg

    India Plans Incentives to Bring In Foreign Manufacturers From Tesla to Glaxo

    (Bloomberg) -- Terms of Trade is a daily newsletter that untangles a world embroiled in trade wars. Sign up here. India is planning to offer 324 companies including Tesla Inc. and GlaxoSmithKline Plc incentives to set up factories in the South Asian nation in a bid to capitalize from the trade war between China and the U.S., according to a document seen by Bloomberg.The government proposes to provide the manufacturers land to set up a factory along with power, water and road access, according to draft of the document prepared by the Department for Promotion of Industry and Internal Trade and Invest India. Other companies that officials will reach out to include Eli Lilly & Co., South Korea’s Hanwha Chemical Corp., and Taiwan’s Hon Hai Precision Industry Co.While the trade war has benefited countries such as Vietnam and Malaysia, rigid land acquisition rules and labor laws have prompted investors to largely ignore India when looking for alternatives to China. The latest proposal may reduce red tape, and set the nation, which expanded at the slowest pace in six years last quarter, on a path to double its gross domestic product to $5 trillion by 2025 -- a goal set Prime Minister Narendra Modi.“While in the initial leg of relocation we have seen companies moving to Vietnam, I don’t think it is too late for India to start making an effort,” said Sonal Varma, chief economist for India and Asia-ex Japan at Nomura Holdings Inc. in Singapore. “India offers a unique advantage of being a huge domestic market too, so it is definitely an opportunity for the government to attract investment.”Under the plan, the government will create a land bank for ready-to-move-in industrial clusters, offer investment and location-based incentives and rationalize anti-dumping duties. The proposal includes incentives for plug-in and hybrid vehicles, fuel efficiency and carbon taxation. For the electronics and telecom sector, flexible employment, manufacturing-related incentives linked to investments and value addition have been sought.The country has made progress, rising 37 spots since 2017 in the World Bank’s ranking for ease of doing business, but it still comes in at 63rd, trailing not only China, but also Rwanda and Kosovo. At present, investors keen on setting up a factory need to acquire land on their own which, in some cases, involves a time consuming process of negotiating with small plot owners to part with their holding.The Prime Minister’s Office is considering the proposal and a decision is expected soon. An email sent to the spokeswoman at the commerce and industry ministry wasn’t immediately answered.Asia’s third-largest economy expanded 5% in the June quarter, with slew of data pointing to weaker economic activity.Getting investment inflows and boosting exports is therefore high on economic agenda of the government. It has already slashed corporate tax rate, making it competitive with rest of Asia, and has relaxed foreign investment rules to attract fund inflows in the country.(Updates with economist’s comment in fourth paragraph)To contact the reporter on this story: Shruti Srivastava in New Delhi at ssrivastav74@bloomberg.netTo contact the editors responsible for this story: Arijit Ghosh at aghosh@bloomberg.net, Unni KrishnanFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Why I might buy this soaring stock alongside the Glaxo (GSK) share price
    Fool.co.uk

    Why I might buy this soaring stock alongside the Glaxo (GSK) share price

    I say GlaxoSmithKline (LON: GSK) is a great investment, but why is this blue-sky biotech making the headlines right now?

  • Reuters - UK Focus

    UPDATE 2-European stocks end flat as defensive gains offset auto slide

    European stocks ended flat on Monday as a spurt of defensive buying over uncertainty surrounding U.S.-China trade talks helped temper losses in the auto sector. The pan-European STOXX 600 index finished little changed, after having spent most of the session in negative territory. The European automobiles and parts sector dropped 2.1%, its steepest fall in about four weeks, with Germany's Volkswagen leading declines after it slashed its operating profit and sales growth outlook due to slowdown in the auto sector.

  • Reuters - UK Focus

    UPDATE 1-GSK sees breakthrough in shingles vaccine output in 2024

    GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production. GSK, Britain's largest drugmaker, had originally envisaged a gradual launch in the United States, its biggest market, but regulators unexpectedly recommended Shingrix not only for people reaching the age of 50 but also to replace an established product. A bioreactor complex in Belgium that makes so-called antigens - proteins that trigger an immune reaction against the shingles virus - is reaching its capacity limits.

  • Reuters - UK Focus

    GSK eyes 'step change' in shingles vaccine output in 2024

    GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production. GSK, Britain's largest drugmaker, had originally envisaged a gradual launch in the United States, its biggest market, but regulators unexpectedly recommended Shingrix not only for people reaching the age of 50 but also to replace an established product. A bioreactor in Belgium that makes so-called antigens - proteins that trigger an immune reaction against the shingles virus - is reaching its capacity limits.

  • No savings at 40? Here are two shares I’d choose to get started
    Fool.co.uk

    No savings at 40? Here are two shares I’d choose to get started

    It's never too late to start investing in the stock market and here are two shares Andy Ross is interested in to benefit from growth and income.

  • Reuters - UK Focus

    UPDATE 2-FTSE 100 underperforms global peers on 3i drop, sterling gains

    London's FTSE 100 underperformed its major global peers on Thursday, suffering its steepest intra-day drop so far this month as falls in private equity company 3i, stocks trading ex-dividend and a stronger pound hammered the exporter-heavy index. The main index fell 0.8% with 3i Group hitting a five-month low after striking a cautious tone about new investment opportunities and as heavyweight components Sainsbury , Shell and GSK traded without dividend entitlement. The mid-cap FTSE 250 was 0.3% lower, with transport operator FirstGroup dropping nearly 20% on its worst day since May 2018 after a bigger first-half loss due to a charge related to its Greyhound bus line business in the U.S..

  • Need To Know: GlaxoSmithKline plc (LON:GSK) Insiders Have Been Selling Shares
    Simply Wall St.

    Need To Know: GlaxoSmithKline plc (LON:GSK) Insiders Have Been Selling Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • £5k to invest? I think the GlaxoSmithKline share price is the best income stock in the FTSE 100
    Fool.co.uk

    £5k to invest? I think the GlaxoSmithKline share price is the best income stock in the FTSE 100

    The GlaxoSmithKline share price has all the hallmarks of a FTSE 100 income stock you can buy and hold for life, argues Rupert Hargreaves.

  • Forget a Cash ISA! I’d invest in these 2 FTSE 100 shares today to make a million
    Fool.co.uk

    Forget a Cash ISA! I’d invest in these 2 FTSE 100 shares today to make a million

    I think these two FTSE 100 (INDEXFTSE:UKX) shares could offer high returns due, in part, to their low valuations.

  • Here's why GlaxoSmithKline plc is a good long-term stock pick
    Stockopedia

    Here's why GlaxoSmithKline plc is a good long-term stock pick

    Most investors would agree that the best quality companies in the stock market often make the best investments as well. I'm talking about some of the most resp8230;

  • 3 reasons I’d buy GSK for my Stocks and Shares ISA right now
    Fool.co.uk

    3 reasons I’d buy GSK for my Stocks and Shares ISA right now

    With 42% growth in the last 10 years and a rock-solid payout history, there's a compelling case for making this dividend share part of your growing portfolio.

  • The GlaxoSmithKline share price won’t stop rising. Is there still time to buy?
    Fool.co.uk

    The GlaxoSmithKline share price won’t stop rising. Is there still time to buy?

    Pharmaceutical giant GlaxoSmithKline plc (LON:GSK) reveals its latest set of quarterly numbers. Paul Summers takes a closer look.

  • GSK raises profit forecast after shingles vaccine sales boost
    Reuters

    GSK raises profit forecast after shingles vaccine sales boost

    The British drugmaker's shares rose as much as 3% to a more than a six-year high after the company said it now expected profit to be roughly flat at constant currency for the year, compared with a previous forecast of a fall of 3% to 5%. CEO Emma Walmsley has embarked on a plan to rejuvenate GSK, which has included the spin off or sale of a number of businesses since she took over in 2017. GSK's leaner structure has also helped the company focus more on its pharmaceuticals business and build a newer pool of treatments, including its shingles vaccine, Shingrix.

  • Reuters - UK Focus

    RPT-Ex-FDA chief Gottlieb sees investment opportunity in 'unloved' antibiotics

    As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics. Since leaving the FDA in April, Gottlieb has revealed little about what types of investments he would make in his new role at New Enterprise Associates, one of the country's largest venture capital firms where he worked prior to his time in government. Near the top of his list are companies researching new kinds of antibiotics, an issue he advocated for while at the FDA.

  • Reuters - UK Focus

    UPDATE 2-Pharma stocks lift FTSE 100 out of red

    A rally in pharmaceutical stocks led by industry giants GlaxoSmithKline and AstraZeneca helped the FTSE 100 outshine most global peers on Wednesday while investors waited for the outcome of the U.S. Federal Reserve's policy meeting. The FTSE 100 reversed early losses to close up 0.3%, with the pharma sub-index scaling an all-time high, up 2.5% after GSK again upgraded its 2019 targets. Moves on both indexes were however subdued with investors waiting for the Fed to announce its policy decision.

  • Reuters - UK Focus

    LIVE MARKETS-Fed watching, Q3 galore and the Xmas Brexit election

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Christmas will come early to the UK this year, precisely on December 12 in the form of a UK general election. It's far from certain however that the polls will deliver anything on Boris Johnson or Jeremy Corbyn's wish list but less than 48 hours ahead of Halloween, investors aren't spooked by the prospect of the process going all wrong.

  • The OUTstanding Top 50 LGBT+ Future Leaders 2019
    Yahoo Finance UK

    The OUTstanding Top 50 LGBT+ Future Leaders 2019

    All of the future models in this list, once they identify as LGBT+, can be in any position in a company and can be any nationality and based in any country.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more